US 11,919,891 B2
Bicyclic compounds useful as GPR120 modulators
Brian Raimundo, Boston, MA (US); Elena S. Koltun, Boston, MA (US); John Griffin, Boston, MA (US); and Eric Stangeland, Boston, MA (US)
Assigned to Valo Health, Inc., Boston, MA (US)
Filed by Valo Health, Inc., Boston, CA (US)
Filed on Dec. 14, 2020, as Appl. No. 17/121,165.
Application 17/121,165 is a continuation of application No. 16/331,928, granted, now 10,865,201, previously published as PCT/US2017/050964, filed on Sep. 11, 2017.
Claims priority of provisional application 62/393,619, filed on Sep. 12, 2016.
Prior Publication US 2021/0347768 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/12 (2006.01); A61P 1/16 (2006.01); A61P 3/08 (2006.01); A61P 3/10 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); C07D 275/06 (2006.01); C07D 401/12 (2006.01); C07D 417/14 (2006.01)
CPC C07D 417/12 (2013.01) [A61P 1/16 (2018.01); A61P 3/08 (2018.01); A61P 3/10 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); C07D 275/06 (2013.01); C07D 401/12 (2013.01); C07D 417/14 (2013.01)] 20 Claims
 
1. A compound of formula:

OG Complex Work Unit Chemistry
wherein
each X independently is CH, CR3, or N;
Y is SO2;
Z is —CH2—, —CH(CH3)—, —C(CH3)2—, —C(CH2CH2)—(cyclopropano), CO, —(CO)CH2—, —CH2CH2—, or —CHCH—;
U is a covalent bond, CH2, —CH(CH3)—, —C(CH3)2—, or —CH2CH2—;
R1 is an optionally substituted 3-7 membered cycloalkyl or heterocyclyl group;
R2 is an optionally substituted 3-7 membered cycloalkyl or heterocyclyl group, an optionally substituted 6-membered aryl group, an optionally substituted 5- or 6-membered heteroaryl group, an optionally substituted 5,6- or 6,6-membered bicyclic aryl or heteroaryl group, or an optionally substituted bicyclic aryl group; and
R3 is a halogen, or an optionally substituted alkyl or alkoxy group.